PTPRK and neoplasm: Studies have found that targeting RSPO3 in PTPRK-RSPO3-fusion-positive human tumor xenografts promotes cell differentiation and inhibits tumor growth, in part suggesting differentiation therapy as a new clinical approach for the treatment of colorectal tumors [36].